ILMN

TOUSI SUSAN H

Known title: SVP, Chief Commercial OfficerCIK: 0001791938

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.

this person other insiders at ILMN

Transaction History

ILMN▼ Sell$201K
ILMN▼ Sell$84K
ILMN▼ Sell$95K
ILMN▼ Sell$100K
ILMN▼ Sell$41K
ILMN▼ Sell$336K
ILMN▼ Sell$314K
ILMN▼ Sell$351K
ILMN▲ Buy$0
ILMN▲ Buy$0
ILMN▼ Sell$446K
ILMN▼ Sell$106K
ILMN▼ Sell$102K
ILMN▼ Sell$106K
ILMN▼ Sell$112K
ILMN▼ Sell$157K
ILMN▼ Sell$108K
ILMN▼ Sell$54K
ILMN▲ Buy$0
ILMN▼ Sell$578K
ILMN▼ Sell$340K
ILMN▼ Sell$39K
ILMN▼ Sell$38K
ILMN▼ Sell$401K
ILMN▼ Sell$41K
ILMN▼ Sell$42K
ILMN▼ Sell$139K

We use analytics to understand how market-wall is used. No personal data is sold.